Hepatocellular carcinoma (HCC)
Conditions
Interventions
A:Group A(n=35) received 100mg lidocaine(100mg,5ml) intraarterially immediately prior to TACE
B:Group B(n=35) received lidocaine-epirubicin-lipiodol emulsion intraarterially during TACE (ratio of lidocaine-epirubicin solution to lipiodol 1:2, using 3-waystopcock).
Sponsors
Department of Radiology, the Second Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Aged >= 18 years. (2) Patients who are diagnosed with HCC via one of the following: (a) typical imaging characteristics on triple-phase dynamic Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) or, (b) histopathological confirmed of HCC. (3) no history of resection or ablation prior to TACE (4) compensated liver function (Child-Pugh class A or B); (5) Eastern Cooperative Oncology Group (ECOG) performance status 0-1; (6) absence of refractory ascites (7) serum creatine <= normal X 1.5;
Exclusion criteria
Exclusion criteria: (1) with main portal venous tumor thrombus (PVTT); (2) presence of distant metastasis (3) uncontrolled or significant cardiovascular disease; (4) administrating non-steroidal anti-inflammatory drugs or steroids periodically; (5) uncontrollable diabetes mellitus with HbA1c >= 8.0 g/dL.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain intensity; | — |
Secondary
| Measure | Time frame |
|---|---|
| analgesic intake; | — |
Countries
China
Contacts
Public ContactYu-Dong Xiao
The Second Xiangya Hospital of Central South University
Outcome results
None listed